Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...
Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
The state has for several years been moving toward competitive integrated employment, in which people with disabilities work ...
On January 22, 2025, the Rotary Club of Dubois County proudly unveiled Jodi Routson’s display in the ATHENA exhibit at the ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...
Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...
Kenvue isn't growing as quickly as Eli Lilly or Zoetis, but it offers investors a strong starting point for dividend income.
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback